2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2146 A Phase 2 study of mosunetuzumab in patients with chronic lymphocytic leukemia with positive measurable residual disease: Trial in progress

Mahesh Swaminathan, MD, Nitin Jain, MD2, Alessandra Ferrajoli III, MD3, Jan A. Burger, MD, PhD4, Maria Teresa Sabrina Bertilaccio, PhD5, Wei Qiao6, Thomas Mathew7, Ana Ayala8, William G. Wierda, MD, PhD9
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background and Significance: Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is the most common leukemia in the US. The introduction of oral targeted agents, particularly Bruton’s tyrosine kinase inhibitors (BTKis) and BCL-2 inhibitors, has transformed the treatment landscape and replaced chemoimmunotherapy. Real-world evidence shows that continuous BTKi therapy is now the most frequent first-line approach. Yet single-agent covalent BTKi produces complete responses (CR) in only 2 to 25% of patients and undetectable measurable residual disease (uMRD4, <0.01% sensitivity) in less than 5%. Prolonged BTKi exposure also carries cumulative risks of cardiac toxicity, hypertension, and the emergence of BTKi resistance with associated BTK mutations in roughly 25 to 70% of patients, which can drive eventual progression. Strategies that clear residual disease and achieve durable uMRD4 are therefore essential to extend time-to-next treatment and create meaningful treatment-free remission intervals.

Mosunetuzumab is a humanized, full-length CD20/CD3 T-cell-engaging bispecific antibody that demonstrated a 60% CR rate in relapsed/refractory (R/R) indolent non-Hodgkin lymphoma and is currently under evaluation in R/R CLL. Complementary data from an alternative CD20/CD3 bispecific antibody, epcoritamab, in the EPCORE-CLL-1 study provide additional proof-of-concept for this therapeutic class in CLL. Building on these observations, we designed an investigator-initiated phase 2 trial to evaluate whether the addition of fixed-duration mosunetuzumab to ongoing BTKi can deepen responses to uMRD4 in patients with CLL who have measurable disease on BTKi.

Study Design and Methods: This single-center, open-label phase 2 study is being conducted at UT MD Anderson Cancer Center (). Participants must meet all of the following criteria: (a) adults with CLL/SLL who have received at least 2 prior lines of systemic therapy that include the current BTKi; (b) high-risk disease defined by any one of the following: progression of disease on a prior covalent BTKi, progression of disease on or within 6 months of venetoclax-based treatment, ≥3 prior treatments, presence of del(17p) and/or TP53 mutation, or unmutated IGHV; and (c) continuous BTKi therapy (covalent or non-covalent) for at least 12 months together with detectable bone marrow (BM) MRD4 by NGS (ClonoSEQ). Those with high disease burden, defined as absolute lymphocyte count greater than 5 × 10⁹/L, largest lymph node >2 cm, or >50% BM involvement by CLL, are excluded.

Participants continue their commercial BTKi. Switching to another BTKi for reasons other than disease progression is permitted. Subcutaneous mosunetuzumab is administered for a fixed duration of 17 cycles (21-day cycles). Cycle 1 uses weekly step-up dosing with 5 mg on day 1, 15 mg on day 8, and 45 mg on day 15. Thereafter, 45 mg is given on day 1 of each subsequent cycle. All patients stop mosunetuzumab after Cycle 17 regardless of MRD status. BTKi will be stopped in patients with BM uMRD4 at the end of Cycle 17. For individuals who remain BM MRD4-positive at that time point, the decision to continue or discontinue BTKi is left to the treating physician. The first 6 patients receive Cycle 1 in the hospital as a safety lead-in. Subsequent patients are planned to be treated entirely in the outpatient setting.

The primary endpoint is the rate of BM uMRD4 by NGS (ClonoSEQ) at the completion of Cycle 17. The target BM uMRD4 rate is 50% and a rate of 20% or lower would be considered not promising. Secondary and exploratory endpoints include safety, progression-free survival, and the uMRD6 rate at the end of cycles 8 and 17. A total of 30 patients will be enrolled. The trial is currently open and actively enrolling patients.

Mahesh Swaminathan, MD: AstraZeneca - Honoraria; MD Education - Honoraria; Lilly - Honoraria; AstraZeneca - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony)